However, comparisons between cfDNA and post-treatment tumour biopsies or peripheral blood mononuclear cells will be needed to definitively test the contribution of mutant HSPC clones to the emergence of TP53 mutants in response to HDM2 inhibition. Here, MDM2 is linked to neoplasm.